What is the long-term trend for Crinetics Pharmaceuticals's stock issuance proceeds?

Over 3 years (2021 to 2025), Crinetics Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $249.54M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Crinetics Pharmaceuticals CRNX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Neurocrine BiosciencesNBIX

$23.6M-26.5%

Viking TherapeuticsVKTX

$450K+28.9%

Catalyst PharmaceuticalCPRX

$3.3M—

Mineralys Therapeutics, Inc.MLYS

$4.06M-97.9%

United TherapeuticsUTHR

$68.3M+311%

Amneal Pharmaceuticals, Inc.AMRX

$38K-44.9%

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's stock issuance proceeds?: Crinetics Pharmaceuticals (CRNX) reported stock issuance proceeds of $380.51M in Q1 2026.
What is the long-term trend for Crinetics Pharmaceuticals's stock issuance proceeds?: Over 3 years (2021 to 2025), Crinetics Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $249.54M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.